Epstein±Barr virus, a human gammaherpesvirus, possesses a unique set of latent genes whose constitutive expression in B cells leads to cell growth transformation. The initiation of this growth transforming infection depends on a viral promoter in BamHI W (Wp) whose regulation is poorly understood. Using Wp reporter constructs in in vitro transfection assays, we found that Wp was 11-to 190-fold more active in B cell than in non-B cell lines and that three regions of the promoter (termed UAS1, UAS2, and UAS3) contributed to transcriptional activation. The upstream regions UAS3 (Ϫ1168 to Ϫ440) and UAS2 (Ϫ352 to Ϫ264) both functioned in a cell lineage-independent manner and were together responsible for the bulk of Wp activity in non-B cells; mutational analysis indicated the importance of a YY1 binding site in UAS2 in that context. By contrast, UAS1 (Ϫ140 to Ϫ87) was B cell specific and was the key determinant of the promoter's increased activity in B cell lines. Mutational analysis of UAS1 sequences combined with in vitro bandshift assays revealed the presence of three binding sites for cellular factors in this region. When mutations that abolished factor binding in bandshift assays were introduced into a Wp reporter construct, the loss of any one of the three UAS1 binding sites was sufficient to reduce promoter activity by 10-to 30-fold in B cells. From sequence analysis, two of these appear to be novel transcription factor binding sites, whereas the third was identified as a cyclic AMP response element (CRE). Our data indicate that this CRE interacts with CREB and ATF1 proteins present in B cell nuclear extracts and that this interaction is important for Wp activity.
INTRODUCTION
Primary infection with Epstein±Barr virus (EBV), a human herpesvirus with B cell growth transforming ability, is associated with a virus-driven expansion of latently infected B lymphocytes. This process, which appears crucial to the successful establishment of the virus carrier state, can be studied in vitro, where the experimental infection of resting B lymphocytes leads to the outgrowth of lymphoblastoid cell lines (LCLs) expressing nine virusencoded latent proteins; the nuclear antigens EBNAs 1, 2, 3A, 3B, 3C, and LP; and three latent membrane proteins (LMP1, LMP2A, and LMP2B) (Kieff, 1996; Rickinson and Kieff, 1996) . Substantial progress has been made in characterising the events occurring during transformation. After binding to the B cell surface receptor CR2 (CD21) (Nemerow et al., 1987; Tanner et al., 1987) and subsequent internalisation of the virus, the first detectable viral transcripts initiate exclusively from a promoter Wp located within each BamHI W repeat of the EBV genome (Alfieri et al., 1991; Sample et al., 1986; Woisetschlaeger et al., 1990) . Although these Wp-initiated transcripts have the potential to encode all six EBNAs, at this early time, viral antigen expression appears to be restricted to EBNA2 and EBNA-LP (Alfieri et al., 1991) . EBNA2, acting either alone or in cooperation with EBNA-LP, then serves to activate a number of viral and cellular promoters that control the expression of genes critical for subsequent stages of growth transformation; these include the upstream BamHI C promoter (Cp), which acts as an alternative promoter for EBNA transcription (Rooney et al., 1992; Sung et al., 1991; , the viral promoters for all three LMPs (Abbot et al., 1990; Fåhraeus et al., 1990; Nitsche et al., 1997; Wang et al., 1990; Zimber-Strobl et al., 1991) , and the promoters of various cellular genes, including CD21, CD23, and cyclin D2 (Cordier et al., 1990; Sinclair et al., 1994; Wang et al., 1987) . EBNA2-mediated activation of Cp is coincident with the broadening of antigen expression to all six EBNAs and with the start of a gradual decline in the levels of Wp transcripts , consistent with the observation that Cp is the dominant EBNA promoter in the majority of established LCLs (Altiok et al., 1992) . In common with other EBNA2-dependent promoters, transactivation of Cp is mediated at least in part through the interaction between EBNA2 and a cellular factor, RBP-J (Grossman et al., 1994; Henkel et al., 1994; Ling et al., 1993; Waltzer et al., 1994; ZimberStrobl et al., 1994) , which recruits EBNA2 to its target sequence. In addition to RBP-J, the Cp EBNA2 response element contains a binding site for a second cellular factor, CBF2 (Ling et al., 1993; Robertson et al., 1995) , and mutations in either of these two cognate sites can abolish EBNA2-dependent Cp activation. Cp activity is also positively regulated through the binding of EBNA1 to high-affinity sites in the upstream oriP sequence (Puglielli et al., 1996; Sugden and Warren, 1989) , the latent origin of plasmid replication.
In contrast to Cp, the factors that govern Wp activity remain poorly characterised. Previous studies have demonstrated that Wp can operate in EBV-negative cells, but there still is no clear consensus on the cell lineage dependence of Wp activity or any detailed understanding of Wp regulatory elements (Contreras-Brodin et al., 1996; Nilsson et al., 1993; Ricksten et al., 1988; Rooney et al., 1992) . Jansson et al. (1992) described an upstream enhancer sequence, located between Ϫ300 and Ϫ135 relative to the RNA start site, which strongly stimulated Wp expression in the EBV-negative Burkitt's lymphoma (BL) cell line DG75, but this element has not been analysed in further detail. More recently, work with larger genomic constructs has shown that the upstream oriP sequences can positively regulate Wp expression in some B cell lines, but this effect was detectable only in reporter constructs in which the intervening Cp region was deleted (Puglielli et al., 1996) . The present study focuses on the cell lineage dependence of Wp activity, on the detailed analysis of regulatory elements upstream of the Wp transcription start site, and on the identification of binding sites for a number of cellular transcription factors critical for Wp function. Effect of deleting 5Ј regulatory sequences on the activity of a series of Wp reporter constructs. The figure is a schematic representation of a homologous series of Wp fragments, cloned into pGL2 Basic, each carrying the Wp RNA start site and different lengths of 5Ј regulatory sequences; the name of each test promoter refers to the upstream limit of Wp sequence. Promoter activity was assayed by quantifying luciferase expression in whole-cell lysates prepared from BJAB cells transiently transfected with derivatives of pGL2 Basic containing the indicated Wp sequences. The reported luciferase values are from a single representative experiment and have been normalised for variations in transfection efficiency by cotransfecting a second constitutive reporter plasmid, CMV␤-Gal. All values are expressed relative to an arbitrary value of 1.0 set for the level of luciferase activity in cells transfected with the empty control vector pGL2 Basic.
RESULTS

Identification of regulatory sequences UAS1, UAS2, and UAS3 within Wp
To characterise the proximal regulatory elements required for Wp expression, we first isolated a subfragment of BamHIW extending from Ϫ1168 to ϩ173 relative to the Wp RNA start site (ϩ1). The position of this subfragment in its immediate context within the viral genome, downstream of oriP and Cp, is illustrated in Fig. 1A . These Wp sequences were introduced into the luciferase reporter pGL2 Basic, such that luciferase expression became dependent on the cloned promoter fragment. The resulting plasmid, Wp1168/Basic, was then used to generate a series of nested deletion mutants (illustrated in Fig. 1B ) carrying truncated Wp sequences down to the minimal Wp87. The effect of these deletions on Wp activity was first determined by introducing the reporter constructs into BJAB, a reference EBV-negative B cell line, and then measuring luciferase expression 24 h posttransfection; in each case, the promoter activity was normalised for differences in transfection efficiency by cotransfecting a second plasmid, CMV␤-Gal, which constitutively expresses ␤-galactosidase.
Representative data from such an experiment are shown in Fig. 1B , in which the activities of the various reporter constructs are expressed relative to that of the pGL2 Basic vector alone. It can be seen that removing the sequences from Ϫ1168 to Ϫ440 caused a significant reduction in Wp activity in BJAB cells, indicating that this distal sequence carries one or more positive regulatory elements. We refer to this cis-acting sequence as upstream activating sequence 3 (UAS3). Further deletion of the sequences from Ϫ440 to Ϫ352 had no discernible effect, whereas removal of the sequences from Ϫ352 to Ϫ264 resulted in a second fall in activity, indicating that this region of the promoter (UAS2) also contains regulatory sites important for Wp expression. Further deletions to Ϫ202, Ϫ170, and Ϫ140 had relatively small effects, but the removal of sequences from Ϫ140 to Ϫ125 resulted in another substantial drop in activity, indicating that a third important element (UAS1) lies downstream of Ϫ140. Although the Wp sequences downstream from Ϫ125 were insufficient to activate luciferase expression when tested in isolation, the data do not eliminate the possibility that there may be regulatory elements downstream of Ϫ125 that contribute to the activity of the Wp140 construct. In summary, Fig. 1 shows that nucleotide sequences extending ϳ1 kb upstream of the Wp transcription start site contribute to a Ͼ1000-fold activation of the promoter over background levels and indicates that this activation is largely dependent on three regions: UAS1 (defined as Ϫ140 to Ϫ87), UAS2 (Ϫ352 to Ϫ264), and UAS3 (Ϫ1168 to Ϫ440).
We next examined the extent to which Wp expression is dependent on host cell type by determining the activity of selected Wp reporter constructs relative to the empty control vector pGL2 Basic in a range of different cell lineages. Table 1 summarises the data from four independent experiments on each of the cell lines tested. The results show that all three cis-acting sequences (UAS1, UAS2, and UAS3) contributed to Wp activation not just in BJAB cells but also in the EBV-negative BL line DG75 and in the EBV-positive BL lines Akata, Eli, and AG876. Based on an average of the data from all five B cell lines, UAS1 contributed to a 12-fold activation in promoter activity (compare Wp140 and Wp87), whereas UAS2 and UAS3 each contributed additional 4-to 5-fold increments in activity (compare Wp440 and Wp264, and Wp1168 and Wp440) . It also is clear from Table 1 that the longest Wp reporter construct (Wp1168) was 11-to 190-fold more active in B cells than in the various non-B cell lines tested; of the latter, Jurkat and CEM are of T cell origin, K562 is a proerythroleukaemic line, and SVK is derived from skin keratinocytes. Furthermore, from assays with the truncated Wp constructs, promoter activity seen in these non-B cells was found to be dependent on UAS3 and UAS2 but not on UAS1. Thus the UAS1-containing Note. Promoter activities were assayed by quantifying luciferase expression in whole-cell lysates prepared from cells transiently transfected with the derivatives of pGL2 Basic. Each experimental value is the mean of four independent experiments and is shown with its standard deviation in parentheses. All values have been corrected for differences in transfection efficiency by cotransfecting a second constitutive reporter plasmid CMV ␤-Gal and are expressed relative to the level of luciferase activity in cells transfected with the empty control vector pGL2 Basic. constructs Wp140 and Wp264 had the same minimal levels of activity in non-B cells as the UAS1-negative construct Wp87; compared with these, larger constructs containing UAS2 showed up to a 10-fold increase in activity, and the additional presence of UAS3 mediated a further 3-to 4-fold increase in some cell lines but not in others. Overall, the data indicate that the promoter proximal element UAS1 functions in a B cell-specific manner, whereas both UAS2 and UAS3 can function in a wider range of cell lineages.
UAS2 contains a YY1 binding site that contributes to Wp activation
In an attempt to pinpoint sequences within UAS2 that contributed to Wp activity, a preliminary mutational analysis was performed by introducing a series of random double nucleotide substitutions, S1±S5, throughout the UAS2 sequence, as detailed in Fig. 2A . The effects of each of these UAS2 mutations was tested in the context of the Wp 440 fragment by transfection into a B cell line, Akata-BL, and into a non-B cell line, K562. The results, illustrated in Fig. 2B , identified one mutation, S2, that caused a significant reduction in Wp activity. We noted that the S2 mutation altered the sequence 5Ј-CCATTTT-3Ј (position Ϫ307 to Ϫ301), which is an exact match with the consensus binding site for a ubiquitously expressed transcription factor YY1 (Park and Atchison, 1991; Shi et al., 1991) . We therefore tested whether YY1 could interact with the relevant Wp sequence by means of a bandshift assay. The results in Fig. 3A demonstrate that incubation of a radiolabeled oligonucleotide probe Ϫ308 to Ϫ279 containing the putative YY1 site with a nuclear extract prepared from DG75 cells results in one abundant complex and several minor species (Fig. 3A , lane 2). The most abundant complex is specific to YY1 because the addition of excess unlabeled probe almost completely abolished formation of this complex (lane 3); in contrast, when a corresponding sequence containing the S2 mutation or an unrelated Oct1 binding sequence was added as competitor, there was no such effect (lanes 4 and 5). Furthermore, this abundant YY1-specific complex was not detectable when the S2-containing sequence was used as a probe (lane 8), although the weak nonspecific complexes were still present. The finding that YY1 specifically interacts with this region of Wp was confirmed in experiments using in vitro translated (IVT) YY1 protein (Fig. 3A , lane 6); this yielded a similar complex that comigrated with the most abundant complex observed in DG75 extracts. The faster migrating complexes seen in this track are probably due to degradation products of IVT YY1 rather than to other proteins in the wheat germ extract because neither these nor the major complex was observed using a mock IVT reaction (lane 7).
To further check the involvement of YY1 in Wp regulation, we compared the activity of wild-type Wp 440 and Wp 440 carrying the S2 mutation in an extended range of cell lines. The results in Fig. 3B show that mutation of the YY1 site reduced Wp expression by 30±40% in the three different B cell lines, DG75, Ramos, and Akata-BL, but had a consistently greater effect in the non-B cell lines Jurkat, CEM, and K562, reducing activity by 65±80%. This presumably reflects the fact that overall, Wp activity is more dependent on UAS2 in non-B cells, where the UAS1 enhancer element is inactive.
Identification of regulatory sites within UAS1
We next focused our attention on the B cell-specific enhancer UAS1 by introducing a series of mutations throughout the Ϫ140 to Ϫ87 region in the context of the Wp440/Basic reporter plasmid. Details of the nucleotide changes in these mutants, designated M1±M9, are given in Fig. 4A . The effects of these changes on Wp activity in a number of different cell lines were then determined by measuring luciferase expression in transient transfection assays. The results in Fig. 4B , summarising data obtained from four independent experiments in each line, show that the mutations designated M2, M3, M7, and M8 all reduced Wp expression in the B cell lines Ramos, Akata-BL, and Eli-BL by 10-to 30-fold. In contrast, these same four mutations reduced Wp activity in K562 cells by only ϳ2-fold, which is consistent with the finding that UAS1 does not contribute significantly to Wp activity in this cell line; similar results were obtained with a second non-B cell line (Jurkat) (data not shown).
Having identified four substitutions within UAS1 that severely abrogated Wp function, we next examined whether these same mutations affected the ability of UAS1 sequences to interact with cellular factors. We designed three overlapping oligonucleotide probes (probe A, Ϫ102 to Ϫ77; probe B, Ϫ115 to Ϫ86; probe C, Ϫ140 to Ϫ99; see Fig. 5 ) that completely spanned UAS1 and used each of these probes in turn to search for interacting proteins in bandshift assays using DG75 nuclear extracts. The results obtained with probe A are illustrated in Fig. 5A . This probe formed multiple complexes (lane 2), all of which could be competed when challenged by the addition of unlabeled probe (lanes 3±5). These complexes were specific to probe A because none of the species could be competed by the addition of probe B (lane 7) or probe C (lane 8). To examine whether the inactivating M8 mutation interfered with the binding of cellular factors to this fragment, we resynthesised probe A to contain the M8 mutation (probe A M8) and used this new sequence as a competitor in the bandshift assay. In contrast to the wild-type probe, this mutant sequence did not compete for complex formation (lane 6), clearly indicating that the M8 mutation prevents the binding of several factors to a single site, designated site A, in UAS1. Figure 5B shows the results of similar experiments with probe B (i.e., Wp sequences Ϫ115 to Ϫ86). This probe formed a single specific complex (lane 2) that was effectively competed by excess unlabeled probe B (lane 4) but not by either probe A (lane 3) or probe C (lane 5). A competitor carrying the inactivating M7 mutation (probe B M7) failed to compete this complex (lane 9), indicating that this substitution prevents the binding of the relevant cellular factor to UAS1. To further characterise the sequences required for binding of this factor, we used various 5Ј and 3Ј truncated versions of probe B to challenge complex formation. Of the 5Ј truncations, the sequence Ϫ110 to Ϫ86 (lane 6) was just as effective a competitor as probe B itself (lane 4), whereas the shorter sequence Ϫ105 to Ϫ86 (lane 7) failed to compete. A 3Ј truncation, the sequence Ϫ115 to Ϫ90 (lane 8), also competed as effectively as probe B. Taken overall, these data show that sequences required for binding of the cellular factor must lie between Ϫ110 and Ϫ90, designated site B. Figure 5C shows the results obtained with probe C, carrying the Wp sequences Ϫ140 to Ϫ99. In this case, three complexes were formed (lane 2), all of which were judged to be specific from the results of competition experiments using excess cold probe (lane 3). To determine whether these three complexes were due to distinct factors binding to separate sites in probe C, we again used a series of truncated sequences as competitors to delineate the 5Ј and 3Ј limits of the binding site. Protein±DNA complexes obtained by incubating probe A (Ϫ102 to Ϫ87) with DG75 nuclear extracts. Lane 1 indicates probe A alone; lane 2, probe with DG75 nuclear extract; lanes 3±5, probe with DG75 nuclear extract and a 1000-, 100-, and 10-fold excess unlabeled probe A, respectively; and lanes 6±8, probe with DG75 nuclear extract and a 1000-fold excess of the indicated competitor DNA fragment. The sequence of probe A and the mutant derivative carrying the M8 substitution are shown below the figure. (B) Protein±DNA complexes obtained by incubating probe B (Ϫ115 to Ϫ86) with DG75 nuclear extracts. Lane 1 indicates probe B alone; lane 2, probe with DG75 nuclear extract; and lanes 3±9, probe with DG75 nuclear extract and a 1000-fold excess of the indicated competitor DNA fragment. Shown below the figure are the sequences of probe B and the mutant derivative carrying the M7 substitution. Truncated fragments carrying the Wp sequences Ϫ110/Ϫ86, Ϫ105/Ϫ86, and Ϫ115/Ϫ90 (not shown) were also used as competitors where indicated. (C) Protein±DNA complexes obtained by incubating probe C (Ϫ140 to Ϫ99) with DG75 nuclear extracts. Lane 1 indicates probe C alone; lane 2, probe with DG75 nuclear extract; and lanes 3±10, probe with DG75 nuclear extract and a 1000-fold excess of the indicated competitor DNA fragment. Shown below the figure is the sequence of probe C and two derivatives carrying the substitutions M2 and M3. Truncated fragments carrying the sequences Ϫ125/Ϫ99, Ϫ120/Ϫ99, Ϫ140/Ϫ111, Ϫ140/Ϫ116, and Ϫ125/Ϫ111 (not shown) were also used as competitors where indicated.
The results of these mapping experiments suggested that all three complexes were due to the binding of multiple factors to the same sequence, designated site C, extending from Ϫ125 (compare lanes 4 and 5) to Ϫ111 (compare lanes 6 and 7). This was further confirmed by the ability of the Ϫ125 to Ϫ111 oligonucleotide to compete out the binding of all three complexes to probe C (lane 8). Importantly, when probe C was resynthesised to contain either of the inactivating mutations M2 or M3, competitor function was lost (lanes 9 and 10), indicating that both of these mutations disrupt the binding of all three factors to this site.
Site A of UAS1 binds members of the CREB/ATF family of transcription factors
An analysis of UAS1 sites B and C using the transcription factor database (Wingender et al., 1996) failed to reveal the presence of any previously defined regulatory motifs, implying that these two elements represent binding sites for as-yet-unrecognised transcription factors. However, inspection of site A revealed the presence of a cAMP response element (CRE), 5Ј-TTACGTAA-3Ј, which differs from the consensus CRE, 5Ј-TGACGTCA-3Ј, at just two positions. CRE sequences bind members of the CREB/ATF family of transcription factors that regulate gene expression in response to changes in cAMP-dependent signaling pathways (Lalli and Sassone-Corsi, 1994; Meyer and Habener, 1993) . To further investigate the role of CREB/ATF factors in Wp activation, we asked whether CREB and ATF1 proteins could interact with site A in bandshift assays. The results shown in Fig. 6 indicate that both IVT CREB (lane 3) and IVT ATF1 (lane 4) bind probe A and that these specific complexes comigrate with the complexes previously observed using DG75 nuclear extracts (lane 2); furthermore, the complexes formed by IVT CREB and IVT ATF1 could be specifically competed by excess probe A but not by probe A containing the M8 mutation (data not shown). As an independent means of demonstrating CREB/ATF binding to site A, we used a monoclonal antibody (mAb) that specifically recognises the leucine zipper/DNA binding domain of CREB/ATF. The addition of this mAb to the binding reaction containing DG75 nuclear extract resulted in multiple supershifted complexes (lane 5) consistent with the binding of CREB/ATF proteins to this sequence; similar supershifted complexes were observed when this same mAb was added to complexes containing IVT CREB and IVT ATF1 (lanes 6 and 7). Together with the data showing that mutation of this CRE element greatly reduces Wp activity (Fig. 4) , these results strongly imply a role for CREB/ATF factors in the regulation of Wp expression in B cells.
DISCUSSION
There are important questions to be addressed regarding Wp function: What are the critical sequences that regulate promoter activity? What are the cellular factors mediating regulation at these sites? To what extent is Wp activity cell lineage restricted? On the first two points, there is relatively little published information and no detailed analysis. On the third point, there is conflicting evidence; thus early reports indicated that Wp contained a B cell-specific enhancer (Jansson et al., 1992; Ricksten et al., 1988) , whereas a more recent report suggested that Wp reporters were active in both B and non-B cell lines (Contreras-Brodin et al., 1996) . The extreme tropism that EBV displays for B lymphocytes in vitro means that it has been difficult to study Wp use by the viral genome during the initiation of a virus infection in other cell types. One exception, however, is the work with human epithelial cell lines in which experimental infection can be achieved in transfectants expressing the EBV receptor CR2 (Knox et al., 1996) . Under these circumstances, most viral transcription appeared to initiate from Qp, an alternative latent cycle promoter that selectively expresses EBNA1 mRNA and is active in EBV-associated malignancies such as BL and nasopharyngeal carcinoma ( 1991, 1995; Smith et al., 1992) . Interestingly, however, low levels of (apparently abortive) Wp transcription were also detectable in these acutely infected epithelial cells, suggesting that Wp may not be entirely under the control of B cell-specific factors.
The present work with a series of Wp reporter constructs shows that overall levels of Wp activity are 11-to 190-fold higher in B than in non-B cell lines. Three upstream regions, UAS3 (Ϫ1168 to Ϫ440), UAS2 (Ϫ352 to Ϫ264), and, particularly, UAS1 (Ϫ140 to Ϫ87), all contribute to the high levels of Wp activity seen in a B cell environment. In contrast, only two of these regions, UAS3 and UAS2, appear to operate in non-B cells, where they account for most of the observed Wp activity. Interestingly, the relative contribution of these two sequences varied from one non-B cell line to another; thus in Jurkat and K562, UAS2 was responsible for the majority of Wp expression, whereas in CEM and SVK, sequences within UAS3 also had weak positive effects. The most important conclusion from these initial assays (Fig. 1, Table 1 ) is that UAS1 functions as a B cell-specific enhancer of Wp transcription. It should be noted that both UAS1 and UAS2 overlap the region of Wp previously described as an enhancer of Wp expression (Jansson et al., 1992; Ricksten et al., 1988) . The results presented here therefore extend these previous findings by showing that there are in fact two sequences in this region of the promoter that can contribute to Wp activation, UAS1 and UAS2, and that a third previously undefined upstream element, UAS3, also exists.
When a number of random mutations within UAS2 were tested in the context of the Wp 440 reporter, one mutant, S2, was identified as having significantly reduced activity (Fig. 2) . This fell within a sequence, 5Ј-CCATTTT-3Ј, matching the consensus binding site for the known transcription factor YY1. Bandshift assays confirmed that IVT YY1 can specifically interact with the Ϫ308 to Ϫ279 subfragment of UAS2, that a similar complex is formed using B cell nuclear extracts, and that this binding is abrogated by the S2 mutation (Fig. 3) . We conclude that YY1 contributes to the activity of UAS2; furthermore, the observation that YY1 is constitutively expressed in many cell types (Shrivastava and Calame, 1994 ) is in accord with our present finding that UAS2 functions in a cell lineage-independent manner. We note, however, that mutation of the YY1 site does not completely abrogate UAS2 activity, even in non-B cell lines in which its effects are most marked. Hence, other, as yet unrecognised, factors may also be important in that context.
The key sequences that determine the preferential activity of Wp in B cells lie within the UAS1 region and were identified by mutational analysis (Figs. 4 and 5) . Two of the inactivating mutations (M2 and M3) were adjacent to each another and lay within a single binding site, site C (Ϫ125 to Ϫ111), identified in bandshift assays.
The three complexes formed at this site were equally affected in competition assays, and all failed to bind to sequences carrying the M2 or M3 mutation, suggesting that all three factors interact with precisely the same sequence. Another inactivating mutation (M7) identified a second site within UAS1, site B (Ϫ110 to Ϫ90), which interacted with a single factor in bandshift assays. The fact that neither site B nor C contains sequences resembling known transcription factor binding sites (Wingender et al., 1996) implies that they may be targets for novel cellular regulators. By contrast, site A (Ϫ102 to Ϫ77), identified through the effects of another mutation (M8), contains a sequence 5Ј-TTACGTAA-3Ј that is closely related to the consensus CREB/ATF binding site. The detection in bandshift assays of multiple protein±DNA complexes at this site (Fig. 5A) is not unexpected because there are many members of this family of bZIP transactivators (Meyer and Habener, 1993) . Using an mAb specific for the bZIP DNA binding domain of CREB/ATF1/ CREM, we confirmed that the complexes formed at site A in the presence of DG75 cell nuclear extracts consist of CREB and ATF1 homodimers, a finding supported by the results of reconstruction experiments demonstrating that IVT CREB and IVT ATF1 produced similar complexes in bandshift assays (Fig. 6) . The fact that the M8 mutation, which disrupts CREB/ATF binding, dramatically reduces the activity of a Wp reporter in B cell lines (Figs. 4 and 5 ) strongly implies that this CRE plays an important role in B cell-specific Wp activation.
Whilst this work was being completed, a report was published (Sugano et al., 1997) that identified another potential regulatory site within Wp. The authors reported that a sequence downstream of UAS1 and close to the Wp transcription start site (Ϫ51 to Ϫ42, 5Ј-GGGGGAC-CAC-3Ј) was capable of binding the transcription factor NF-B (consensus site 5Ј-GGGACTTTCC-3Ј). We have been unable to repeat this observation using various probes spanning the Wp sequence in this region, even using B cell extracts that contained abundant NF-B as detected by binding to the known NF-B site in the HIV LTR (unpublished data). Sugano et al. (1997) also reported that transient overexpression of the p50 subunit, or coexpression of the p50 and p65 subunits of NF-B, enhanced the activity of a cotransfected Wp reporter in the human embryonic kidney cell line 293. For this reason, we specifically mutated the putative NF-B site [introducing the same mutations reported by Sugano et al. (1997) to block NF-B binding] and tested these in the context of our standard Wp440 reporter; there was no detectable effect on Wp activity in the B cell lines BJAB, DG75, and Akata-BL. Further work will be required to reconcile these apparently contradictory findings.
From the present study, we propose that a number of binding sites for cell regulatory proteins influence Wp activity in B cells, but among the most important are three adjacent sites lying within the UAS1 region 87±140 nucleotides upstream of the transcription start site. One of these sites binds members of the CREB/ATF family, whereas the identity of the factors binding at the other two sites remains to be determined. Interestingly, we found that although UAS1 functions in a B cell-specific manner and its activity is strongly dependent on the integrity of all three sites, the cellular factors binding to these sites in bandshift assays are not themselves restricted to B cells. Thus similar patterns of bandshifts to those illustrated in Fig. 5 were also produced in the presence of extracts from non-B cell lines such as K562 and Jurkat (unpublished data) . This indicates that the mere presence of these factors is not sufficient for UAS1 activity and suggests that additional components or activation steps are required that are only functional in B cells. In this context, it is interesting to note that a novel pathway of CREB activation has recently been reported in a B cell system, where in response to surface immunoglobulin ligation, CREB is phosphorylated not by the usual protein kinase A pathway but rather by protein kinase C (Xie et al., 1996) .
Finally, we draw attention to the fact that the present analysis has focused on regulatory sequences within 1 kb of the Wp transcription start site. Although we believe that these sequences will play a role in Wp activation in EBV-infected B cells, clearly, promoter activity may be further modulated by long-range effects in the broader context of the viral genome, and these may become particularly important as the infection proceeds. Thus others have found that placing an oriP sequence upstream of a Wp reporter can enhance promoter activity in certain cell lines, presumably through the recruitment of EBNA1 (Puglielli et al., 1996) . However, in larger genomic constructs carrying oriP-Cp-Wp in their natural orientation, Wp activity is suppressed by the presence of a functional Cp, perhaps reflecting transcriptional interference from the upstream promoter (Puglielli et al., 1997; Woisetschlager et al., 1990) . Interestingly, in such genomic constructs, Cp transcription was itself enhanced by a region within Wp (Puglielli et al., 1997; Walls and Perricaudet, 1991) that includes the UAS1 and UAS2 elements identified in the present work. It remains to be seen whether the particular binding sites shown here to influence Wp activity are also responsible for effects on Cp. Clearly, the complex interplay between these two adjacent promoters and their regulatory elements remains important for a proper understanding of the early events of B cell infection.
MATERIALS AND METHODS
Maintenance of cell lines
Transient assays were performed using a number of B and non-B cell lines. BJAB is an EBV-negative B lymphoma cell line, Ramos and DG75 are EBV-negative BL cell lines, Akata-BL and Eli-BL are EBV-positive BL cell lines showing a form of infection in which EBNA1 is the only viral protein detected, and AG876 is a BL cell line that has switched to a form of infection in which all nine viral latent proteins are expressed. Of the non-B cell lines, Jurkat and CEM are of leukaemic T cell origin, K562 is a proerythroleukaemic line, and SVK was generated by SV40-induced transformation of human keratinocytes. All cell lines except SVK were maintained as suspension cultures in growth medium containing RPMI 1640 supplemented with 2 mM glutamine, gentamicin (100 mg/l), and 10% (v/v) selected foetal calf serum (Life Technologies). SVK cells were grown in Joclics medium supplemented with 8% foetal calf serum, 2 mM glutamine, and 0.4 g/ml hydrocortisone.
Plasmid constructions
Throughout this work, we used standard recombinant DNA methods as described by Sambrook et al. (1989) , and all plasmid manipulations were performed using the Escherichia coli strain XL1 Blue (Stratagene). The luciferase reporter construct pGL2 Basic was obtained from Promega. pGL2 Basic is a promoterless luciferase expression vector used to monitor promoter activity of test DNA fragments. CMV␤-Gal consists of the E. coli ␤-galactosidase gene driven by the human cytomegalovirus (CMV) immediate-early promoter. The full-length cDNAs for rat CREB and human ATF1 and for human YY1 were kindly provided by Dr. H. Hurst (ICRF Oncology Unit, Hammersmith Hospital, U.K.) and by Dr. J. Sinclair (Department of Medicine, University of Cambridge, Addenbrookes Hospital, U.K.), respectively. For the purpose of in vitro transcription±translation experiments, all cDNAs were cloned under the control of the bacteriophage T7 promoter in the expression vector pcDNA3 (InVitrogen). Synthetic oligonucleotides for site-directed mutagenesis and bandshift probes were purchased from Alta Bioscience, The University of Birmingham.
The starting point for this work was the 1343-bp BamHI±AvrII subfragment of the EBV BamHI W repeat, which carries the nucleotide sequences of the BamHI W promoter Wp from Ϫ1168 to ϩ175 (Baer et al., 1984; Sample et al., 1986) ; the nucleotide sequences are numbered with respect to the Wp RNA start site (see Fig. 1 ). This fragment, termed Wp1168, was inserted between the BglII and NheI sites of the luciferase reporter vector pGL2 Basic such that luciferase expression became dependent on the cloned promoter fragment. In the resulting plasmid Wp1168/Basic, Wp sequences are flanked upstream and downstream by unique KpnI and HindIII sites, respectively. The Wp440 and Wp352 derivatives of pGL2 Basic were constructed by ligating the BglII±Hin-dIII and SacI±HindIII subfragments of Wp1168, respectively, into pGL2 Basic. The Wp264 derivative was constructed by cloning the AvrII±AvrII subfragment into the NheI site of pGL2 Basic. The shortest Wp construct, Wp87, was generated by deleting the sequences between the SacI and SnaBI sites of Wp264/Basic and recircularising the vector. Five additional derivatives (Wp232, Wp202, Wp170, Wp140, and Wp105) containing nested deletions in the 5Ј Wp regulatory sequences were constructed by PCR amplification of Wp sequences. In each case, the appropriate 5Ј primer (containing additional flanking sequences carrying a SacI site) and a common 3Ј primer, which annealed just downstream of the HindIII site in pGL2 Basic, were used to amplify a specific subfragment of Wp. The amplified DNA products were digested with SacI and HindIII, and the resultant Wp-containing fragments ligated into pGL2 Basic. All Wp derivatives carry the same BamHI W and pGL2 Basic DNA sequences downstream of the Wp RNA start site. Derivatives of Wp carrying specific mutations in either UAS1 or UAS2 were constructed by site-directed mutagenesis of the Wp440 fragment, cloned in M13 mp18, using a synthetic mutagenic oligonucleotide and the Sculptor in vitro mutagenesis system (Amersham). After verification of the presence of the desired mutation by dideoxy sequencing (Pharmacia T7 sequencing kit), mutant Wp440 sequences were transferred into pGL2 Basic as KpnI±HindIII fragments.
Transient transfections
For electroporation of suspension cell cultures, 10 7 cells in 400 l of HEPES-buffered DME containing 10% FCS, 8 g of luciferase reporter, and 2 g of CMV␤-Gal were placed in a 1-ml electroporation cuvette with an electrode spacing of 4 mm. The cells were pulsed at 960 F and at a predetermined optimum voltage for each cell line (310 V for CEM and 270 V for all other cell lines) using a BioRad Gene Pulser and then transferred to 5 ml of RPMI 1640 growth medium in 3.5-cm-diameter cell culture dishes. Cell suspensions were cultured for 16±24 h at 37°C before being harvested and used to prepare whole-cell lysates for reporter gene assays.
Adherent SVK cells were transfected using a modification of the DEAE-dextran method. Briefly, 1 ϫ 10 6 cells were plated onto 25-cm 2 flasks, and on the next day, the monolayers were washed with PBS to remove residual serum. Then, 2.5 ml of transfection mixture containing 200 g/ml DEAE dextran, 200 mM chloroquine, 8 g of luciferase reporter, and 2 g of CMV␤-Gal in DME was added to each flask, and the cells were incubated for 2 h at 37°C. The transfection mixture then was removed, and the cells were washed with PBS and treated with 10% DMSO in PBS for 2 min, followed by two washes with PBS and the addition of growth medium.
Reporter gene assays
The activity of different Wp constructs was assayed by quantifying luciferase expression in whole-cell lysates prepared from cells transiently transfected with derivatives of pGL2 Basic. At 16±24 h posttransfection, cells were washed in PBS and then lysed in 200 l of lysis buffer (100 mM HEPES, pH 8, 2 mM magnesium chloride, 5 mM dithiothreitol, 2% Triton X-100). Luciferase activity was determined by the addition of 100 l of luciferase assay reagent (20 mM glycylglycine, pH 7.9, 5 mM magnesium chloride, 0.1 mM EDTA, 33 M dithiothreitol, 270 M coenzyme A, 470 M beetle luciferin, and 530 M ATP) to 50 l of lysate and then measuring light emission for 10 s in a Berthold LB9501 luminometer. The luciferase activity in each sample was then normalised for variations in transfection efficiency by measuring the level of ␤-galactosidase expression from a cotransfected CMV␤-Gal plasmid. After incubation of the residual cell lysate at 50°C for 1 h, a 20-l aliquot was mixed with 200 l of substrate (AMPGD, Tropix) and left for 1 additional h at room temperature. ␤-Galactosidase activity was determined by the addition of 300 l of Emerald reagent (Tropix) and then measurement of light emission for 5 s in a Berthold LB9501 luminometer.
Nuclear extract preparation
Crude nuclear extracts for use in bandshift experiments were prepared using a simplified method of Dignam et al. (1983) . Briefly, 10±20 ϫ 10 6 cells were pelleted, washed once in PBS, and then lysed in 100 l of buffer A (10 mM HEPES, pH 7.9, 1.5 mM magnesium chloride, 10 mM potassium chloride, 0.5 mM dithiothreitol, 0.2% Nonidet P-40) and freshly supplemented with the protease inhibitors (100 g/ml) phenylmethylsulfonyl fluoride, leupeptin, benzamidine, and aprotinin. The nuclei were collected by centrifugation at 13,000 rpm for 1 min, resuspended in 100 l of buffer C (5 mM HEPES, pH 7.9, 420 mM NaCl, 1.5 mM magnesium chloride, 26% glycerol, 0.5 mM dithiothreitol, 0.2 mM EDTA, and protease inhibitors as before) and incubated for an additional 30 min on ice. The samples were centrifuged again at 13,000 rpm for 1 min to pellet cell debris, and the cleared nuclear extracts were stored in small aliquots at Ϫ70°C until needed.
Bandshift assays
The sequences of double-stranded oligonucleotide probes for use in bandshift assays are shown in the relevant figures. Probes were end-labeled using polynucleotide kinase (Boehringer-Mannheim) and ␥-32 P-ATP (3000 Ci/mmol; Amersham). In vitro binding reactions typically contained 2 l of nuclear extract (5±10 g of protein), 2 g of poly(dI/dC) (Pharmacia), and 1 fmol of radioactively labeled DNA fragment (added last). Where indicated, competitor DNA fragments (1 pmol) were added to the binding reaction before the addition of the labeled probe. This mixture was incubated on ice for 30 min before being loaded onto a 5% polyacrylamide gel containing 0.5ϫ TBE buffer and electrophoresed for 2±4 hr at 30 mA. Gels were dried and exposed to x-ray film overnight at Ϫ20°C. In experiments involving the binding of CREB/ATF factors to probe A, poly(dI/dC) was replaced with herring sperm DNA (Sigma) as the nonspecific competitor. Where indicated, 2±5 l of in vitro translated YY1, CREB, and ATF1 proteins, prepared using an in vitro wheat germ transcription/translation system (Promega TNT), were included in the binding reactions in place of nuclear extracts. For supershift experiments, the binding reactions were incubated with 2 l of mAb (25C10G, Santa Cruz Biotechnology), which specifically recognises the conserved bZIP domain of CREB/ATF/ CREM proteins, for 30 min at room temperature before the addition of the labeled fragment.
